Levosimendan Reverses Cardiac Malfunction and Cardiomyocyte Ferroptosis During Heart Failure with Preserved Ejection Fraction via Connexin 43 Signaling Activation
ConclusionRegular long-term levosimendan administration can benefit cardiac function in a mouse model of HFpEF with metabolic syndromes (namely, obesity and hypertension) by activating connexin 43-mediated mitochondrial protection and sequential ferroptosis inhibition in cardiomyocytes.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Calcium | Cardiology | Cardiovascular | Eating Disorders & Weight Management | Heart | Heart Failure | Hypertension | Molecular Biology | Obesity | Sports Medicine | Study